Oasis has initiated a shareholder derivative lawsuit against the directors of Kobayashi Pharmaceutical, targeting former chairman and others over issues related to the red yeast rice controversy. The lawsuit claims damages amounting to 13.5 billion yen. This legal action follows concerns raised about the company's handling of the red yeast rice product, which has implications for its governance and accountability. Oasis, a Hong Kong-based fund, holds a 5.93% stake in En Japan, indicating its active involvement in corporate governance matters.